Managing Postpartum Depression in Clinical Practice

EP: 1.Defining Postpartum Depression

EP: 2.Recognizing and Differentiating Postpartum Depression

EP: 3.Impact on Quality of Life in Postpartum Depression

EP: 4.Risk Factors for Postpartum Depression

EP: 5.Collaborative Role of Providers for Screening, Diagnosis, and Referrals in Postpartum Depression

EP: 6.Screening and Referral Recommendations in Postpartum Depression

EP: 7.Improving Patient Communication in Postpartum Depression

Now Viewing

EP: 8.Managing Postpartum Depression in Clinical Practice

Video content above is prompted by the following:

When providers identify positive postpartum depression screens, several immediate resources are available while patients await specialized care. Postpartum Support International serves as a primary resource, offering local therapist directories, warm phone lines for patient connections, and free virtual support groups for various populations, including LGBTQ+ individuals, those who experienced pregnancy loss, and NICU families. State psychiatric consultation lines provide additional support for providers needing immediate guidance on treatment plans or hospitalization decisions.

Effective postpartum depression treatment often requires collaboration between providers, with dyad therapy being particularly beneficial. Postpartum depression responds well to pharmacological intervention, with many patients achieving remission and returning to baseline functioning. Sertraline is commonly used, but providers should consider patients’ previous medication responses when selecting treatments. All selective serotonin reuptake inhibitors are considered safe for use during pregnancy and breastfeeding, making treatment decisions more flexible.

Providers must address patients’ preconceptions about psychiatric medications, often stemming from social media, family experiences, or cultural beliefs. Common concerns include addiction potential, personality changes, and indefinite medication use. Effective communication involves explaining medications as temporary tools—“ladders out of the hole”—with plans to taper after 8 to 12 months of stability. Providers should assess patients’ medication attitudes, provide evidence-based resources, and allow time for decision-making rather than rushing treatment decisions.